World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
45
Citations
8733
World Ranking
16321
National Ranking
904

Chun-wa Chung publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Chun-wa Chung sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 119 publications — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Chun-wa Chung D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Chun-wa Chung sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 45 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Chun-wa Chung is affiliated with GlaxoSmithKline in the United Kingdom and has contributed extensively to the fields of biochemistry, genetics, and molecular biology, with specific emphasis on molecular biology and hematology. Their publication record indicates engagement with both foundational and applied research areas within medicine, notably oncology and organic chemistry.

The primary topics of Chun-wa Chung's research include:

  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments
  • Ubiquitin and Proteasome Pathways
  • Peptidase Inhibition and Analysis
  • Mass Spectrometry Techniques and Applications
  • Click Chemistry and Applications
  • Analytical Chemistry and Chromatography

Chun-wa Chung has coauthored numerous scientific articles alongside frequent collaborators such as Rab K. Prinjha, Paul Bamborough, Inmaculada Rioja, Emmanuel H. Demont, and Laurie Gordon. These collaborations highlight a focused research community within their specialty.

The scientist has published papers in several prominent journals, with a significant number featured in the Journal of Medicinal Chemistry, followed by contributions to ACS Medicinal Chemistry Letters, bioRxiv, Communications Biology, and Angewandte Chemie International Edition. Frequent publication venues include:

  • Journal of Medicinal Chemistry
  • ACS Medicinal Chemistry Letters
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Communications Biology
  • Angewandte Chemie International Edition

Recent publications by Chun-wa Chung include:

  • "Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation" (2020, Science)
  • "Author Correction: Cycloalkane-modified amphiphilic polymers provide direct extraction of membrane proteins for CryoEM analysis" (2022, Communications Biology)
  • "Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs" (2021, Angewandte Chemie International Edition)
  • "Structural Insights into PROTAC-Mediated Degradation of Bcl-xL" (2020, ACS Chemical Biology)
  • "GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins" (2020, Journal of Medicinal Chemistry)

The work of Chun-wa Chung predominantly explores mechanisms of protein degradation and inhibition, with particular attention to PROTACs (proteolysis-targeting chimeras) and bromodomain inhibitors, which are crucial in cancer and immunoinflammation studies. These areas reflect ongoing interest in therapeutic strategies targeting cellular regulatory pathways through chemical biology and medicinal chemistry approaches.

Best Publications

  • A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

    Laurens Kruidenier;Chun-wa Chung;Zhongjun Cheng;John Liddle

  • Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

    Huw D Lewis;John Liddle;Jim E Coote;Stephen J Atkinson

  • Biophysics in drug discovery: impact, challenges and opportunities

    Jean-Paul Renaud;Chun-wa Chung;U. Helena Danielson;Ursula Egner

  • Discovery and Characterization of Small Molecule Inhibitors of the Bet Family Bromodomains.

    Chun-wa Chung;Hervé Coste;Julia H. White;Olivier Mirguet

  • Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

    Olivier Mirguet;Romain Gosmini;Jérôme Toum;Catherine A. Clément

  • Identification of a Novel Series of Bet Family Bromodomain Inhibitors: Binding Mode and Profile of I-Bet151 (Gsk1210151A).

    Jonathan Seal;Yann Lamotte;Frédéric Donche;Anne Bouillot

  • Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery.

    Chun-wa Chung;Anthony W. Dean;James M. Woolven;Paul Bamborough

  • Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

    Paul Bamborough;Hawa Diallo;Jonathan D. Goodacre;Laurie Gordon

  • The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor

    Romain Gosmini;Van Loc Nguyen;Jérôme Toum;Christophe Simon

  • Identification of a glycosaminoglycan binding surface on human interleukin-8.

    Gabriele S. V. Kuschert;Arlene J. Hoogewerf;Amanda E. I. Proudfoot;Chun-wa Chung

  • Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition

    Natalie H. Theodoulou;Paul Bamborough;Andrew J. Bannister;Isabelle Becher

  • Author Correction: Cycloalkane-modified amphiphilic polymers provide direct extraction of membrane proteins for CryoEM analysis

    Unknown

  • Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.

    Peiling Chen;Apirat Chaikuad;Paul Bamborough;Marcus Bantscheff

  • Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP.

    Henrik Johansson;Henrik Johansson;Yi-Chun Isabella Tsai;Ken Fantom;Chun-Wa Chung

  • The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains

    Antje Dittmann;Thilo Werner;Chun-Wa Chung;Mikhail M. Savitski

  • 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain

    Emmanuel H. Demont;Paul Bamborough;Chun-wa Chung;Peter D. Craggs

  • Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

    Robert P. Law;Stephen J. Atkinson;Paul Bamborough;Chun-wa Chung

  • Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe

    Philip G. Humphreys;Paul Bamborough;Chun-wa Chung;Peter D. Craggs

  • Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry

    Sue E. Hutchinson;Melanie V. Leveridge;Michelle L. Heathcote;Peter Francis

  • Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.

    Robert P Law;Joao Nunes;Chun-Wa Chung;Marcus Bantscheff

  • Selectivity of Kinase Inhibitor Fragments

    Paul Bamborough;Murray J. Brown;John A. Christopher;Chun-wa Chung

  • Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.

    Paul Bamborough;Chun-wa Chung;Rebecca C. Furze;Paola Grandi

  • Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors

    Emmanuel H. Demont;Chun-wa Chung;Rebecca C. Furze;Paola Grandi

Frequent Co-Authors

Rab K. Prinjha
Rab K. Prinjha GlaxoSmithKline (United Kingdom)
Gerard Drewes
Gerard Drewes GlaxoSmithKline (United Kingdom)
Marcus Bantscheff
Marcus Bantscheff GlaxoSmithKline (United Kingdom)
Tony Kouzarides
Tony Kouzarides University of Cambridge
Mark A. Dawson
Mark A. Dawson Peter MacCallum Cancer Centre
Udo Oppermann
Udo Oppermann University of Oxford
Mikhail M. Savitski
Mikhail M. Savitski European Bioinformatics Institute
Christopher J. Schofield
Christopher J. Schofield University of Oxford
James H. Naismith
James H. Naismith Rosalind Franklin Institute
David F. Tough
David F. Tough GlaxoSmithKline (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Chemistry opens doors to various related fields that combine science with practical applications. For those interested in an interdisciplinary approach, exploring an cost of criminal justice degree can inform decisions about balancing education expenses with career goals.

Many students begin with an accessible foundation such as an accredited online criminal justice associate degree, which offers practical skills useful in scientific investigation roles that overlap with law enforcement.

Alternatively, fields like legal assistance related to scientific patents and regulations often require a paralegal associate degree. This pathway supports careers at the intersection of law and science, providing organizational skills and legal expertise relevant to chemists.

Graduates focusing on the commercial side of Chemistry might explore becoming a pharmaceutical sales representative. Understanding the pharma sales rep salary and career paths is essential for those interested in blending scientific knowledge with business and communication skills.

Best Scientists Citing Chun-wa Chung

Trending Scientists

Recently Published Articles